Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2020-03-02

2020

Balala Aggeliki

Γαρυφαλλιά Πουλάκου, Επίκουρη Καθηγήτρια, Ιατρική Σχολή ΕΚΠΑ, Επιβλέπουσα
Σωτήριος Τσιόδρας, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Ν. Συρίγος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ

Κλινική έκβαση νοσηλευομένων ουδετεροπενικών ασθενών με καρκίνο του πνεύμονα ανάλογα με την βαρύτητα της ουδετεροπενίας

Greek

Clinical outcome of patients with neutropenic lung cancer depending on the gravity of neutropenia

INTRODUCTION: Lung Cancer claims first place in cancer in the world ranking. The treatment is based on its stage and requires the combination of surgery, chemotherapy, immunotherapy and radiotherapy. The main side effect of chemo- radiotherapy is marrow suppression and reduced neutrophil production. The consequence of this is neutropenia. Although patients receive systemic growth factors (G-CSF), they are often inadequate and have severe neutropenia, accompanied by fever and infections, many times life threatening.
PURPOSE: The purpose of the present research was to study the neutropenic patients with lung cancer, who receive chemotherapy, what factors are associated with neutropenia, and what their clinical outcome is.
MATERIAL AND METHODS: The material and method used was the study of files over the years 2017 and 2018 at two Oncological units “EVAGGELISMOS General Hospital and “General Hospital for Thoracic Diseases of Athens SOTIRIA”.
RESULTS: Neutropenies that occur in patients with lung cancer are mild, moderate, and severe and are significantly related to age, gender, treatment cycle, growth factor administration, and type of cancer.
CONCLUSIONS: Older ages and women versus men are higher at neutropenia rates. In the first line of chemotherapy, there were the highest rates of neutropenia. Febrile neutropenia, moderate to severe, presented several cases and were diagnosed with documented infections where they were admitted to the hospital for further intravenous antibiotics. Also another interesting point of the research was that in the cases treated 50% were with NSCLC and the remaining 50% were SCLC. These patients had to postpone some cycle of treatment and then reduce doses of chemotherapy.

Health Sciences

Neutropenia, Chemotherapy, Lung cancer, Infections

No

0

Yes

99

132

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2897430